Hypertension in Elderly – Pathogenesis and Treatment

Q4 Medicine Open Hypertension Journal Pub Date : 2019-01-01 DOI:10.15713/ins.johtn.0164
T. Padmanabhan, M. Azam
{"title":"Hypertension in Elderly – Pathogenesis and Treatment","authors":"T. Padmanabhan, M. Azam","doi":"10.15713/ins.johtn.0164","DOIUrl":null,"url":null,"abstract":"“Old age is like a plane flying through a storm. Once you’re aboard, there’s nothing you can do.” -Golda Meir Hypertension (HTN) is a leading risk factor in the aged for cardio/cerebrovascular events, the prevalence of which increases with age. Pathophysiologically, it differs from HTN of the young (altered structure and function of conduit arteries vis-a-vis resistance vessels of the young). Older hypertensives have altered or downregulated biological functions, have multiple comorbidities warranting polypharmacy with attendant drug interactions� Elevated blood pressure (BP) is the most common cause of mortality over the globe, being responsible for about 13% of all deaths every year, accounting for about 57 million disability-adjusted life years�[1] The prevalence of elevated BP worldwide in 2008 was about 40%, being highest in the WHO African region (46%) and lowest in the Americas (35% in both sexes). The prevalence of uncontrolled HTN has increased by approximately 600 million compared to that in 1980�[2] The burden of HTN is rising globally due to the growth of the obese and aged population and is projected to affect around 70% of the global population by 2025�[3] Abstract","PeriodicalId":38918,"journal":{"name":"Open Hypertension Journal","volume":"40 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Hypertension Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15713/ins.johtn.0164","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

“Old age is like a plane flying through a storm. Once you’re aboard, there’s nothing you can do.” -Golda Meir Hypertension (HTN) is a leading risk factor in the aged for cardio/cerebrovascular events, the prevalence of which increases with age. Pathophysiologically, it differs from HTN of the young (altered structure and function of conduit arteries vis-a-vis resistance vessels of the young). Older hypertensives have altered or downregulated biological functions, have multiple comorbidities warranting polypharmacy with attendant drug interactions� Elevated blood pressure (BP) is the most common cause of mortality over the globe, being responsible for about 13% of all deaths every year, accounting for about 57 million disability-adjusted life years�[1] The prevalence of elevated BP worldwide in 2008 was about 40%, being highest in the WHO African region (46%) and lowest in the Americas (35% in both sexes). The prevalence of uncontrolled HTN has increased by approximately 600 million compared to that in 1980�[2] The burden of HTN is rising globally due to the growth of the obese and aged population and is projected to affect around 70% of the global population by 2025�[3] Abstract
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
老年高血压的发病机制与治疗
“老年就像一架在暴风雨中飞行的飞机。一旦上了船,你就无能为力了。高血压(HTN)是老年人心/脑血管事件的主要危险因素,其患病率随着年龄的增长而增加。病理生理上,它不同于年轻人的HTN(导管动脉相对于年轻人的阻力血管的结构和功能改变)。老年高血压患者的生物功能改变或下调,有多种合共病,需要多种药物相互作用。血压升高(BP)是全球最常见的死亡原因,每年约占死亡总数的13%,约占5700万残疾调整生命年[1]。2008年,全球血压升高的患病率约为40%。在世卫组织非洲区域最高(46%),在美洲最低(男女均为35%)。与1980年相比,未控制的HTN患病率增加了约6亿人[2]。由于肥胖和老龄化人口的增长,HTN的负担在全球范围内不断上升,预计到2025年将影响全球约70%的人口[3]
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Open Hypertension Journal
Open Hypertension Journal Medicine-Cardiology and Cardiovascular Medicine
自引率
0.00%
发文量
0
期刊最新文献
Implementation of a Resistant Hypertension Control Program in a Low-income Primary Care Setting in a High-Income Country: Lessons Learned and Global Applicability Troponin and B-type Natriuretic Peptides Biomarkers in the Management of Hypertension Hypertension in end-stage kidney disease Confirming a Diagnosis of "Hypertension" Sodium-glucose Co-transporter 2 Inhibitors and Blood Pressure Reduction among Patients with Diabetes, Cardiovascular Disease, Chronic Kidney Disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1